Oruka Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Oruka Therapeutics, Inc. (ORKA) reported Increase Decrease In Operating Lease Liability of -$263.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-10
- Oruka Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$138.00K.
- Oruka Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$125.00K.
- Oruka Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was $20.00K.
- Oruka Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$439.00K.
- Oruka Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$448.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 5 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 8 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 11 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$138.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$263.00K 10-Q · filed 2026-08-10 | -$243.00K derived: sum of 3 quarters · filed 2026-08-10 | -$682.00K derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2026-03-31 | -$125.00K 10-Q · filed 2026-05-13 | -$105.00K derived: sum of 2 quarters · filed 2026-05-13 | -$544.00K derived: sum of 3 quarters · filed 2026-05-13 | -$552.00K derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$419.00K derived: sum of 2 quarters · filed 2026-03-12 | -$427.00K derived: sum of 3 quarters · filed 2026-08-10 | -$448.00K 10-K · filed 2026-03-12 | |||
| 2025-09-30 | -$439.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$447.00K derived: sum of 2 quarters · filed 2026-08-10 | -$468.00K 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | -$8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$29.00K 10-Q · filed 2026-08-10 | |||||
| 2025-03-31 | -$21.00K 10-Q · filed 2026-05-13 | ||||||
| 2024-12-31 | -$14.00K 10-K · filed 2026-03-12 | ||||||
| 2024-09-30 | $6.00K 10-Q · filed 2025-11-12 | ||||||
| 2024-06-30 | $4.00K 10-Q · filed 2025-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |